Peter Hoogerbrugge, PhD Pediatric Oncologist, Prinses Maxima Centrum, Utrecht Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia https://ash.confex.com/ash/2018/webprogram/Paper112599.htmlLees meer
0120HEM1291233
Stephan A. Grupp, MD, PhD Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia https://ash.confex.com/ash/2018/webprogram/Paper112599.htmlLees meer
0120HEM1291233
James Baumgardner, PhD Precision Health Economics, Los Angeles, CA CAR-T Therapy Displays Favorable Gains in Health Outcomes and Competitive Cost-Effectiveness When Compared with Past Innovative Cancer Treatments https://ash.confex.com/ash/2018/webprogram/Paper116763.htmlLees meer
0120HEM1291233
Francesco Passamonti, MD Dipartimento di Medicina e Chirurgia, Università dell'Insubria, Varese, Italy Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study https://ash.confex.com/ash/2018/webprogram/Paper115350.htmlLees meer
0120HEM1291431
Susanne Isfort Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN) https://ash.confex...Lees meer
0120HEM1291431
Ruben Mesa, PhDRuben Mesa PhD UT Health San Antonio Cancer Center, San Antonio Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial https://ash.confex.com/ash/2018/webprogram/Paper111929.html...Lees meer
0120HEM1291431
Prof dr. Arjan van de Loosdrecht, internist-hematoloog, Amsterdam UMC, Amsterdam Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study https://ash.confex.com/ash/2018/webprogram/Paper111134.htmlLees meer
0120HEM1291431
×

Ask Speakers

×

Medical Information Request